Maternal Mental Health Awareness Week: May 1-7, 2023
May 4, 2022 is World Maternal Mental Health Day, coming together to increase awareness of perinatal mood and anxiety disorders.
New Research from the CWMH: More Data on the Reproductive Safety of Lurasidone and Quetiapine
New findings from the National Pregnancy Registry for Atypical Antipsychotics provide reassuring data regarding the safety of prenatal exposure to lurasidone and quetiapine in a sample of well-characterized participants.
What Has a Greater Effect on Children’s Behavior: Prenatal Exposure to Antidepressants or Maternal Depression?
Maternal depression during the third trimester, not prenatal SSRI exposure, was associated with higher levels of internalizing and anxiety behaviors in children from 3 to 12 years of age.
Is it Safe to Use Atomoxetine (Strattera) During Pregnancy?
Based on this large cohort study including 990 pregnancies with first trimester exposure to atomoxetine, the researchers observed no increase in major congenital malformations overall and no statistically increased risk estimates for cardiac or limb malformations.
Weekly Roundup for APRIL 14, 2023: Recent Publications in Women’s Mental Health
Every week we review the most recent publications in women’s mental health.
Sleep Disturbance During Pregnancy and Risk for Perinatal Depression
Evidence suggests that sleep disturbance during pregnancy is associated with higher risk of perinatal depression, especially during the third trimester.
When a New Baby Comes Home, Do Moms and Dads Get Depressed Together?
Should we also be assessing women’s partners to determine if they have postpartum depression?
Essential Reads: Transcranial Magnetic Stimulation for Perinatal Depression
TMS in pregnancy and the postpartum period appears to be a promising treatment option with no reports of adverse obstetric outcomes or congenital malformations.